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Biliary tract carcinomas (BTCs) constitute a clinically 
and genetically heterogeneous group of malignancies 
arising from the biliary epithelium. The four established 
clinicopathological subtypes of BTCs (intrahepatic chol-
angiocarcinoma, ICC; perihilar cholangiocarcinoma, 
PCC; distal extrahepatic cholangiocarcinoma, ECC; gall-
bladder cancer, GBC) show partially overlapping genom-
ic profiles, yet the prevalence of the various molecular 
subgroups vary significantly between these groups 
(Fig. 1). ICCs show the highest abundance of targetable 
genomic alterations, while ECCs, PCCs and GBCs are 
characterized by a high prevalence of currently undrug-
gable alterations including activating mutations in KRAS. 
Personalized treatment for the distinct molecular sub-
groups of BTC is rapidly emerging, gradually shifting the 
treatment landscape for this difficult-to-treat tumor en-
tity. In 2020, the FDA granted approval for pemigatinib, 
a selective FGFR 1–3 inhibitor, for pre-treated unresect-
able cholangiocarcinoma harboring genomic rearrange-
ments of FGFR2, based on data from the phase II 
FIGHT-202 trial [1]. Both pemigatinib and infigratinib, 
another selective FGFR 1–3 inhibitor, are currently being 
evaluated against chemotherapy for 1st line treatment in 
phase III trials (NCT03656536, NCT03773302) [2]. 
FGFR2 blockade in FGFR2-altered BTCs is consistently 
associated with high response rates, making this approach 
also highly feasible for molecular conversion treatment in 
the curative-intent setting [3]. The second subgroup of 
BTCs with a clinically already advanced targeting strategy 
is those harboring IDH1 hotspot mutations. For this sub-
group, the phase III ClarIDHy trial showed improved 
progression-free survival (PFS), however not overall sur-
vival (OS), for treatment with IDH1 inhibitor ivosidenib 
over placebo [4]. Consequently, ivosidenib is undergoing 
FDA priority review in this indication. Beyond FGFR2 
and IDH1 alterations, precision treatment for several oth-
er smaller molecular subgroups of BTC is gaining in-
creased attention. Less common molecular subgroups in-
clude BTCs with high microsatellite instability (MSI-H) 
[5] and BTCs harboring oncogenic mutations with in the 
BRAF serine/threonine kinase [6] as well as tumors har-
boring mutations or amplifications of the HER2/neu on-
coprotein.
The article by Jacobi et al. [7] within this issue reports 
focuses on the latter subgroup. The authors report the 
prevalence of HER2/neu genomic alterations in a large 
real-life cohort of BTCs and illustrate therapeutic target-
ing of HER2/neu in BTC by reporting 3 example cases. 
The HER2/neu oncoprotein is among the best established 
oncogenic drivers and therapeutic targets in precision 
oncology. Also for BTCs, HER2/neu is an attractive mo-
lecular target, particularly since – in contrast to FGFR2 
and IDH1 alterations – HER2/neu activating mutations 
or copy number alterations also relatively frequently oc-
cur in PCC, ECC and GBC. In this respect, results report-
ed by Jacobi et al. are in agreement with previously re-
ported findings [8–10].
Despite the abundance of HER2/neu alterations and 
the available of a rapidly growing range of potent and se-
lective drugs targeting HER2/neu, only limited data are 
available from prospective trials investigating therapeutic 
targeting of HER2/neu in BTCs. In the NCT02091141 
(“My Pathway”) phase 2 prospective study, 11 patients 
with BTCs harboring Her2 overexpression or amplifica-
tion [8], or activating mutation [3], received a combina-
tion treatment with trastuzumab and pertuzumab. Four 
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of these patients showed a partial response and further 3 
patients stable disease for more than 4 months [11]. Fur-
ther retrospective studies and case reports reported on 
small number of patients treated with heterogeneous 
combinations of Her2 antibodies +/– chemotherapy [12]. 
Less encouraging prospective treatment data are available 
for tyrosine kinase inhibitor lapatinib, evaluated in two 
phase 2 studies, showing lack of activity in molecular un-
selected patients’ population [13, 14]. Two of the patients 
reported by Jacobi et al. [7] received oral HER2 inhibitor 
neratinib within a non-specified clinical trial. The phase 
2 SUMMIT basket trial treated patients with BTCs har-
boring activating mutations in HER2/neu with neratinib, 
observing an objective response rate of 2/19 and disease 
control rate of 6/19 patients, respectively. Median PFS in 
this cohort was reported to be 1.8 months [15]. Trials test-
ing newer HER2-targeting agents in BTC are ongoing in-
cluding antibody-drug conjugate trastuzumab deruxte-
can [16], a compound with very encouraging response 
rates in HER2-positive breast [17], gastric [18] and 
colorectal cancers [19].
While targeting HER2/neu in BTCs shows consider-
able promise, there are also significant limitations and 
unmet challenges to overcome. Thus, it remains unclear 
how to best distinguish in a given case between a HER2/
neu oncogenic driver alterations and mere passenger 
events. Deciphering the role of HER2/neu in an individ-
ual tumor requires both detailed information on the al-
teration identified and the genetic context it occurs in. 
For instance, while HER2/neu amplifications in a KRAS 
wild type background are well-established targets for pre-
cision treatment, validated across several entities and 
with proven therapeutic potential, the oncogenic impact 
of activating HER2/neu mutations are much less clear. 
Similarly, the best way of targeting HER2/neu activating 
mutations in a given entity remains to be established [20]. 
From Jacobi et al. [7], we neither learn about the co-alter-
ations found in BTCs with identified HER2/neu altera-
tions nor essential details about HER2/neu copy numbers 
or HER2/neu mutation variant allele frequencies. Both 
critical parameters also are not routinely reported by 
Foundation One CDx, which in the context of HER2/
neu-directed precision treatment, is a major limitation of 
the test.
In summary, prospective precision oncology trials es-
tablishing the best possible targeting strategies for the dis-
tinct type of HER2/neu alterations found in BTC are ur-
gently required in order to exploit the full potential of 
HER2/neu targeting in BTCs. In the meantime, detailed 
reporting of real-world data can help to better establish a 
precision oncology workflow for HER2/neu testing and 
targeting in BTC. From a clinician’s perspective, many 
questions remain including timing and modality of test-
ing (tissue vs. liquid biopsy, which test?) as well as correct 
interpretation of results in the genomic context of a given 
tumor and the individual patient’s clinical situation.
Fig. 1. Targetable genomic alterations in distinct anatomical sub-
types of biliary tract carcinoma (BTC). ICC, intrahepatic cholan-
giocarcinoma; PCC, perihilar cholangiocarcinoma; ECC, distal ex-
trahepatic cholangiocarcinoma; GBC, gallbladder cancer; dMMR/
MSI-H, mismatch repair-deficient/microsatellite instability-high; 
HRD, homologous recombination deficiency; SNV, single nucleo-
tide variant (modified from Akhoundova, Hussung and Fritsch, 
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